Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Center for Microbiology Research, Kenya Medical Research Institute; Nairobi, Kenya.
J Acquir Immune Defic Syndr. 2021 May 1;87(1):e150-e158. doi: 10.1097/QAI.0000000000002625.
Preexposure prophylaxis (PrEP) discontinuation rates in clinical trials and demonstration projects have been well characterized; however, little is known about discontinuation in routine public health settings in sub-Saharan Africa. Understanding discontinuation in nonstudy settings is important for establishing expectations for PrEP continuation in national programs and for facilitating effective PrEP scale-up.
We conducted in-depth interviews with 46 individuals who had initiated PrEP at 25 HIV comprehensive care clinics (CCCs) in central and western Kenya and whose clinic records indicated they had discontinued.
Many of our study participants discontinued PrEP when their perceived risk decreased (eg, hiatus or end of a sexual relationship or partner known to be living with HIV became virally suppressed). Others reported discontinuation due to side effects, daily pill burden, preference for condoms, or their partner's insistence. Participant narratives frequently described facility level factors such as stigma-related discomforts with accessing PrEP at CCCs, inconvenient clinic location or operating hours, long wait times, and short refill dates as discouraging factors, suggesting actionable areas for improving PrEP access and continuation.
Clients frequently make intentional decisions to discontinue PrEP as they weigh different prevention options within the context of complex lives. Many clients will decide to discontinue PrEP when perceiving themselves to be at reduced risk and PrEP counseling must include provisions for addressing seasons of risk. PrEP will not be the right prevention method for everyone, or forever. Expanding PrEP access points and increasing sex-positive messaging may facilitate PrEP being a better option for many.
临床试验和示范项目中已充分描述了暴露前预防(PrEP)的停药率;然而,在撒哈拉以南非洲的常规公共卫生环境中,人们对停药情况知之甚少。了解非研究环境中的停药情况对于确定国家计划中 PrEP 持续使用的预期以及促进 PrEP 的有效推广非常重要。
我们对在肯尼亚中部和西部的 25 个艾滋病毒综合护理诊所(CCC)开始接受 PrEP 的 46 名个体进行了深入访谈,他们的诊所记录表明他们已经停药。
我们的许多研究参与者在他们认为风险降低时停止了 PrEP(例如,性伴侣暂停或结束,或已知的 HIV 阳性伴侣病毒载量得到抑制)。其他人则因副作用、每日服药负担、对避孕套的偏好或伴侣的坚持而报告停药。参与者的叙述经常描述了设施层面的因素,例如在 CCC 获得 PrEP 时与耻辱感相关的不适、诊所位置或营业时间不方便、长时间等待以及短的续药日期,这些因素令人望而却步,表明在改善 PrEP 获得和持续使用方面有可采取行动的领域。
客户经常根据复杂生活中的不同预防选择做出有意停止 PrEP 的决定。当许多客户认为自己的风险降低时,他们将决定停止 PrEP,并且 PrEP 咨询必须包括解决风险季节的措施。PrEP 不一定适合每个人,或者永远都是正确的预防方法。扩大 PrEP 获得途径和增加性健康正面信息传递可能会使 PrEP 成为更多人的更好选择。